

Researchers in Korea study new set of biomarkers for diabetes, obesity treatment

14 October 2022 | News

Research collaboration between Prof Antonio Gasbarrini team at Gemelli Hospital and Asian Biotech companies, Coree and Dx&Vx



According to International Diabetes Federation, approximately 537 million adults (20-79 years) are living with diabetes worldwide and 206 million adults of the Western Pacific region including China, Japan, and South Korea have diabetes in 2021.

Studies have shown that Asians are at higher risk of developing type 2 diabetes compared with people of European ancestry even at a lower BMI. Currently, 60% of the world's diabetic population is Asian. Also, the number of obese people has rapidly increased across the world with the obesity prevalence exceeding 50% in many countries. Therefore, the prevention of diabetes and obesity is very important as well as the treatment of diseases.

For these reasons, a clinical study has been initiated with the strong commitment of Chongyoon Lim, the President of Coree group and Hanmi Pharmaceutical and the Chairman of the Korea Biotechnology Industry Organization, and is currently under 50% progress. The novelty of this study is the correlation between the new set of biomarkers from multi-omics data and the state of disease that could be used for preventing and treating these diseases in the following digital therapy solution.

To develop the digital therapy solution, DxVx (acquired in 2021 by Chongyoon Lim) will participate in this clinical study and develop the digital prevention and treatment solution for improving the symptoms of these metabolic syndromes by modulating microbiota with development of new probiotics.